Browse by Series:

Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

Howard Kaufman, MD
Published: Thursday, May 04, 2017



Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
Slider Left
Slider Right


Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x